Literature DB >> 11410575

Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction.

J J McMurray1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11410575      PMCID： PMC1729819          DOI： 10.1136/heart.86.1.97

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  19 in total

1.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

Authors:  B Pitt; P A Poole-Wilson; R Segal; F A Martinez; K Dickstein; A J Camm; M A Konstam; G Riegger; G H Klinger; J Neaton; D Sharma; B Thiyagarajan
Journal:  Lancet       Date:  2000-05-06       Impact factor: 79.321

2.  Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan.

Authors:  K Dickstein; J Kjekshus
Journal:  Am J Cardiol       Date:  2001-03-15       Impact factor: 2.778

3.  Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.

Authors:  G A Riegger; H Bouzo; P Petr; J Münz; R Spacek; H Pethig; V von Behren; M George; H Arens
Journal:  Circulation       Date:  1999-11-30       Impact factor: 29.690

4.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators.

Authors:  K Swedberg; M Pfeffer; C Granger; P Held; J McMurray; G Ohlin; B Olofsson; J Ostergren; S Yusuf
Journal:  J Card Fail       Date:  1999-09       Impact factor: 5.712

5.  Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.

Authors:  M A Pfeffer; J McMurray; A Leizorovicz; A P Maggioni; J L Rouleau; F Van De Werf; M Henis; E Neuhart; P Gallo; S Edwards; M A Sellers; E Velazquez; R Califf
Journal:  Am Heart J       Date:  2000-11       Impact factor: 4.749

6.  Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators.

Authors:  J N Cohn; G Tognoni; R Glazer; D Spormann
Journal:  Eur J Heart Fail       Date:  2000-12       Impact factor: 15.534

7.  Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators.

Authors:  P H Dunselman
Journal:  Int J Cardiol       Date:  2001-02       Impact factor: 4.164

8.  The safety and tolerability of candesartan cilexetil in CHF.

Authors:  E Erdmann; M George; B Voet; G Belcher; D Kolb; S Hiemstra; M Pietrek; P Held
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2000-09       Impact factor: 1.636

Review 9.  Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial.

Authors:  B Pitt; P Chang; P B Timmermans
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727

10.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

Authors:  R Garg; S Yusuf
Journal:  JAMA       Date:  1995-05-10       Impact factor: 56.272
View more
  1 in total

Review 1.  Angiotensin receptor blockers and risk of myocardial infarction: systematic review.

Authors:  Michael A McDonald; Scot H Simpson; Justin A Ezekowitz; Gabor Gyenes; Ross T Tsuyuki
Journal:  BMJ       Date:  2005-09-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.